scholarly journals ROS1 positive non-small cell lung cancer with pulmonary embolism in a 22-year woman

2020 ◽  
Vol 90 (3) ◽  
Author(s):  
Ananda Datta ◽  
Satya Padmaja Mantha ◽  
Suvradeep Mitra ◽  
Prasanta Mohapatra ◽  
M Srikanth Goud ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pulmonary Embolism ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Ros1 Rearrangement

ROS1-rearrangement occurs in 1-2% of non-small cell lung cancer (NSCLC). This mutation is predominantly seen in relatively young, non-smoker, female with adenocarcinoma. Association of pulmonary embolism with ROS1-rearranged NSCLC has been suggested. We report a case of a 22-year-old woman with ROS1-positive NSCLC and pulmonary embolism. This case possibly represents the youngest patient in the literature.

scholarly journals Clinicopathological significance and diagnostic approach of ROS1 rearrangement in non-small cell lung cancer: a meta-analysis: ROS1 in non-small cell lung cancer

2018 ◽  
Vol 33 (4) ◽  
pp. 520-527 ◽  
Author(s):  
Jungho Yang ◽  
Jung-Soo Pyo ◽  
Guhyun Kang
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Test Accuracy ◽  
Small Cell Lung ◽  
Histologic Subtype ◽  
Molecular Tests ◽  
Ros1 Rearrangement

Purpose: The aim of this study was to investigate the rate of ROS1 rearrangement and concordance between ROS1 immunohistochemistry (IHC) and molecular tests in non-small cell lung cancer (NSCLC). Methods: The study included 10,898 NSCLC cases from 21 eligible studies. ROS1 rearrangement rates were evaluated in NSCLC by a meta-analysis, including subgroup analyses. In addition, we performed a concordance analysis and a diagnostic test accuracy review of ROS1 IHC in NSCLC. Results: The estimated overall rate of ROS1 rearrangement and IHC positivity was 2.4% (95% confidence interval (CI) 1.5, 3.7). In the subgroup analysis, which was based on tumor subtype, the rate of ROS1 rearrangement and IHC positivity was 2.9% (95% CI 1.9, 4.5) and 0.6% (95% CI 0.3, 1.2) in adenocarcinoma and non-adenocarcinoma, respectively. The overall concordance rate between ROS1 IHC and molecular tests was 93.4% (95% CI 78.3, 98.2). In ROS1 IHC positive and negative cases, the concordance rates were 79.0% (95% CI 43.3, 94.9) and 97.0% (95% CI 83.3, 99.5), respectively. The pooled sensitivity and the specificity of ROS1 IHC were 0.90 (95% CI 0.70, 0.99) and 0.82 (95% CI 0.79, 0.84), respectively. The diagnostic odds ratio and the area under the curve of the summary receiver operating characteristic curve were 118.01 (95% CI 11.81, 1179.67) and 0.9417, respectively. Conclusion: The rates of ROS1 rearrangement differed by tumor histologic subtype in NSCLC. ROS1 IHC may be useful for the detection of ROS1 rearrangement in NSCLC. Detailed criteria for evaluating ROS1 IHC are needed before it can be applied in daily practice.

ROS1 rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predicitve impact and genetic variability.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 8066-8066
Author(s):  
Matthias Scheffler ◽  
Anne Maria Schultheis ◽  
Cristina Teixido ◽  
Sebastian Yves Friedrich Michels ◽  
Daniela Morales-Espinosa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Genetic Variability ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Ros1 Rearrangement

scholarly journals P3.02a-031 Non-Small Cell Lung Cancer Targeted Therapy in Case of ROS1 Rearrangement

2017 ◽  
Vol 12 (1) ◽  
pp. S1180-S1181 ◽  
Author(s):  
Elena Reutova ◽  
Konstantin Laktionov ◽  
Merab Ardzinba ◽  
Nadezhda Meshcheriakova
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Ros1 Rearrangement ◽  
Cancer Targeted Therapy
Sign in / Sign up

Export Citation Format

Share Document